Episode
The Future of Psychedelic Medicine with Ismail Lourido Ali, JD
- Published
- May 28, 2026
- Duration seconds
- 3144
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/episodes/the-future-of-psychedelic-medicine-with-ismail-lourido-ali-jd/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/the-future-of-psychedelic-medicine-with-ismail-lourido-ali-jd.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the drug policy reform movement for over a decade, informed by half a lifetime of diverse personal experience with psychedelics and other substances. In this conversation, Ismail explores the rapidly evolving landscape of psychedelic medicine, reflecting on the field's major milestones, challenges, and future possibilities. He discusses how public perception has shifted over the past decade, the role of state-level psychedelic reforms, and the tensions created by commercialization, overhype, and competing regulatory models. Much of the discussion focuses on the recent federal executive order related to psychedelic research and drug development, including what it may mean for FDA approval timelines, right-to-try access, rescheduling, and public health standards. Throughout, Ismail emphasizes that psychedelics are not a "silver bullet," but tools that require strong systems of care, thoughtful policy, and community support to be integrated responsibly into healthcare and society. In this episode, you'll hear: How public attitudes toward psychedelics have shifted over the past decade Major milestones that expanded psychedelic policy reform beyond federal drug approval The promises and pitfalls of increased visibility, commercialization, and hype in the psychedelic field What the recent federal executive order on psychedelics actually does and does not do An explanation of right-to-try laws, FDA approval pathways, and the complexities of rescheduling psychedelic medicines Why maintaining rigorous evidentiary standards is essential for the long-term credibility…